PRODUCT

°í°´¸¸Á·À» À§ÇØ Áö¼ÓÀûÀ¸·Î °í¹ÎÇϰí Çõ½ÅÇÏ¿© ÃÖ°íÀÇ Ç°ÁúÀ» Á¦°øÇÕ´Ï´Ù.

R&D reagents

Product > R&D reagents
Rivastigmine tartrate, 98% (HPLC)
CAS No 71830-100mg
Á¦Ç°¹øÈ£ AK Sci.(USA)
Á¦Á¶»ç ¼öÀÔ»ê
Àç°í 1 EA
±Ý¾× 95,000¿ø
Æ÷Àå´ÜÀ§
Æ÷Àå´ÜÀ§



N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate



 

 

¡Ø È­Çиí : Rivastigmine tartrate, 98% (HPLC)

 

¡Ø µî±Þ : APIs and Bioactives > AChR Agonists, Alzheimers

 

¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 100mg , 1g , 5g

 

¡Ø È­ÇÐ½Ä : C14H22N2O2.C4H6O6

 

¡Ø CAS # : [129101-54-8]



 

IDENTITY
CAS Registry #:

 

[129101-54-8]

MDL Number: MFCD03700731
MF: C14H22N2O2.C4H6O6
MW: 400.4235
SPECIFICATIONS & PROPERTIES
Purity: 98% (HPLC)
Available Spectra: NMR, LCMS, HPLC
Physical Form: White to off-white crystalline powder
Melting Point: 115-128¡ÆC
Optical Rotation: +4.7¡Æ (c=5, EtOH)
Long-Term Storage:

 

Store at room temperature

Shipping: Regulated for Shipping
UN #: 2811
Hazard Class: 6.1
Packing Group: III

BIOLOGICAL INFO
Application(s): Cholinesterase inhibitor

REVIEW

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

REFERENCES
[1] Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimers disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25.
[2] Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimers disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8.
[3] Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimers disease. Clin Ther. 2004 Jul;26(7):980-90.
[4] Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimers disease. Behav Neurol. 1998;11(4):211-216.

Risk Description(s)
R36/37/38: Irritating to eyes, respiratory system and skin

Safety Description(s)
S24/25: Avoid contact with skin and eyes.